Skip to content
Biodatica
Start free

C4 Therapeutics, Inc.

Scottsdale, Arizona

OncologyCAR-TPhase IIIListed · CCCC

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

2w agoTrial registeredJul 1, 2026Source filing (opens the source filing in a new tab)

Momentum

88no change

Momentum 88 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jul 1, 2026

    Multiple Myeloma · NOT_YET_RECRUITING · sponsor: Medical College of Wisconsin · BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

    ClinicalTrials.gov · NCT07009899 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Feb 18, 2026

    Multiple Myeloma, Relapsed/Refractory Multiple Myeloma · RECRUITING · sponsor: C4 Therapeutics, Inc. · A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT07284758 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Jul 9, 2025

    Multiple Myeloma, Newly Diagnosed · RECRUITING · sponsor: Intergroupe Francophone du Myelome · Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

    ClinicalTrials.gov · NCT06918002 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources